FAP and neoplasm: Those proteins (Table 3) have been tested in preclinical studies showing promising results; for instance, the fusion protein sc40-FasL was tested against tumor stroma in mice by intravenous administration, showing no signs of systemic toxicity and preventing the growth of FAP-positive cells [148].